Titan Pharmaceuticals (NASDAQ:TTNP) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 4.6 %

NASDAQ:TTNP opened at $3.38 on Thursday. The business’s 50-day simple moving average is $3.95 and its 200 day simple moving average is $5.20. Titan Pharmaceuticals has a one year low of $3.15 and a one year high of $14.80.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.